原发胃肠道淋巴瘤患者25例临床分析
Clinical Analysis of 25 Cases of Primary Gastrointestinal Lymphoma (PGI) Patients
DOI: 10.12677/acm.2025.154989, PDF,    科研立项经费支持
作者: 姜文敬:青岛大学医学部,山东 青岛;康复大学青岛中心医院血液科,山东 青岛;王 玲*:康复大学青岛中心医院血液科,山东 青岛
关键词: 胃肠道淋巴瘤临床特征治疗效果预后Gastrointestinal Lymphoma Clinical Features Treatment Efficacy Prognosis
摘要: 目的:分析原发胃肠道淋巴瘤患者的临床特征、治疗效果与预后。方法:收集我院2012年9月至2025年1月诊治的25例PGI患者的临床资料和实验室指标等,对临床特征、治疗效果与预后进行回顾性分析,影响预后的单因素分析采用Kaplan-Meier法,多因素分析采用Cox比例风险模型,探讨相关临床指标对PGI患者预后的影响。结果:PGI-DLBCL患者占PGI-NHL患者人数的52%,是PGI-NHL的主要病理类型,患病人群多为中老年男性,临床症状主要表现为腹痛(52%)、腹部不适(24%)、腹胀(12%)及消化道出血症状(黑便8%),病变多累及胃(44%),回肠8例(32%)及盲肠(24%),B症状发生率较低(68%)。12例(48%)患者为中高危,10例(40%)分期为III~IV。在中位随访时间9.47个月里,有11例患者达CR,2例患者达PR,2例达SD,10例出现PD,仅有1例患者因为疾病进展而死亡。所有患者的2年PFS率和2年OS率分别为45.3%和94.4%。单因素分析显示,LDH水平、Lugano分期和Ki67与PGL患者预后有关。将上述变量纳入多因素COX回归模型,结果显示,LDH水平升高,Lugano分期为III~IV是PGL患者预后的独立危险因素。结论:1. PGL患者的肿瘤细胞来源以B细胞为主,DLBCL为其最常见的病理类型。患者人群多为中老年男性,临床症状主要表现为腹痛,且B症状发生率较低。2. LDH水平的升高和Lugano分期较晚(III~IV)是PGL患者预后的不利因素,可能有助于医生对患者进行风险分层,采取更为个性化的治疗措施。
Abstract: Objective: To analyze the clinical characteristics, treatment outcomes, and prognosis of patients with primary gastrointestinal lymphoma (PGI). Methods: We collected clinical data and laboratory indicators from 25 PGI patients diagnosed and treated at our hospital between September 2012 and January 2025. A retrospective analysis was performed on the clinical features, treatment efficacy, and prognosis. Univariate analysis of prognostic factors was conducted using the Kaplan-Meier method, while multivariate analysis was performed with the Cox proportional hazards model to explore the influence of clinical indicators on the prognosis of PGI patients. Results: Among PGI-NHL patients, 52% were diagnosed with PGI-DLBCL, which is the most common pathological type. The majority of the affected patients were middle-aged and elderly males. The most common clinical symptoms were abdominal pain (52%), abdominal discomfort (24%), bloating (12%), and gastrointestinal bleeding (melena in 8%). The lesions predominantly affected the stomach (44%), ileum (32%), and cecum (24%). The incidence of B symptoms was relatively low (68%). Twelve patients (48%) were classified as intermediate to high-risk, and 10 patients (40%) were staged as III~IV. During a median follow-up period of 9.47 months, 11 patients achieved complete remission (CR), 2 achieved partial remission (PR), 2 had stable disease (SD), and 10 showed progressive disease (PD). Only one patient died due to disease progression. The 2-year progression-free survival (PFS) rate and 2-year overall survival (OS) rate were 45.3% and 94.4%, respectively. Univariate analysis revealed that LDH levels, Lugano staging, and Ki67 were associated with prognosis. In multivariate Cox regression analysis, elevated LDH levels and advanced Lugano staging (III-IV) were identified as independent prognostic factors for PGI patients. Conclusion: 1. PGI tumors are primarily of B-cell origin, with DLBCL being the most common pathological type. The affected population is predominantly middle-aged and elderly males, and clinical symptoms are mainly characterized by abdominal pain, with a low incidence of B symptoms. 2. Elevated LDH levels and advanced Lugano staging (III~IV) are unfavorable prognostic factors in PGI patients. These factors may help clinicians in risk stratification and the development of more personalized treatment strategies.
文章引用:姜文敬, 王玲. 原发胃肠道淋巴瘤患者25例临床分析[J]. 临床医学进展, 2025, 15(4): 732-741. https://doi.org/10.12677/acm.2025.154989

参考文献

[1] Koch, P., del Valle, F., Berdel, W.E., Willich, N.A., Reers, B., Hiddemann, W., et al. (2001) Primary Gastrointestinal Non-Hodgkin’s Lymphoma: I. Anatomic and Histologic Distribution, Clinical Features, and Survival Data of 371 Patients Registered in the German Multicenter Study GIT NHL 01/92. Journal of Clinical Oncology, 19, 3861-3873. [Google Scholar] [CrossRef] [PubMed]
[2] Ghimire, P. (2011) Primary Gastrointestinal Lymphoma. World Journal of Gastroenterology, 17, 697-707. [Google Scholar] [CrossRef] [PubMed]
[3] Dawson, I.M.P., Cornes, J.S. and Morson, B.C. (1961) Primary Malignant Lymphoid Tumours of the Intestinal Tract. Report of 37 Cases with a Study of Factors Influencing Prognosis. Journal of British Surgery, 49, 80-89. [Google Scholar] [CrossRef] [PubMed]
[4] 徐敏, 戈伟. 原发性胃弥漫性大B细胞淋巴瘤临床特点及误诊分析[J]. 临床误诊误治, 2017, 30(5): 7-11.
[5] 程平, 王秋香, 程辉, 等. 20例原发性胃肠道非霍奇金淋巴瘤临床分析[J]. 临床内科杂志, 2023, 40(5): 342-343.
[6] 宋丽萍, 侯惠莲, 赵辉, 等. 原发性胃肠道非霍奇金淋巴瘤的临床特征及疗效分析[J]. 癌症, 2004, 23(6): 685-688.
[7] 刘祥祥, 王健红, 郝彩霞, 等. 17例原发胃肠道弥漫大B细胞淋巴瘤临床病例分析[J]. 现代肿瘤医学, 2018, 26(17): 2756-2759.
[8] Ziepert, M., Hasenclever, D., Kuhnt, E., Glass, B., Schmitz, N., Pfreundschuh, M., et al. (2010) Standard International Prognostic Index Remains a Valid Predictor of Outcome for Patients with Aggressive CD20+ B-Cell Lymphoma in the Rituximab Era. Journal of Clinical Oncology, 28, 2373-2380. [Google Scholar] [CrossRef] [PubMed]
[9] 韩彩娟. 170例弥漫大B细胞淋巴瘤的临床分析[D]: [硕士学位论文]. 银川: 宁夏医科大学, 2021.
[10] 杨艳丽, 王晶, 赵灵芝, 等. 40例原发性胃肠道弥漫大B细胞淋巴瘤临床特征、细胞来源与预后分析[J]. 癌症, 2008, 27(6): 636-641.